New heart drug SGC001 takes first step in healthy volunteers

NCT ID NCT07079618

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a single dose of the experimental drug SGC001 in 49 healthy adults to check its safety and how the body processes it. The drug is being developed for heart attacks, but this trial did not involve people with heart disease. The goal was to gather essential safety information before testing in patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTERIOR MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Anzhen Hospital Capital Medical University

    Beijing, Beijing Municipality, 100013, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.